Varex Imaging Corporation

NasdaqGS:VREX Stock Report

Market Cap: US$528.2m

Varex Imaging Valuation

Is VREX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VREX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$8.09
Fair Value
55.1% overvalued intrinsic discount
5
Number of Analysts

Below Fair Value: VREX ($12.55) is trading above our estimate of fair value ($8.09)

Significantly Below Fair Value: VREX is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VREX?

Key metric: As VREX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VREX. This is calculated by dividing VREX's market cap by their current revenue.
What is VREX's PS Ratio?
PS Ratio0.6x
SalesUS$820.80m
Market CapUS$528.17m

Price to Sales Ratio vs Peers

How does VREX's PS Ratio compare to its peers?

The above table shows the PS ratio for VREX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.2x
ANGO AngioDynamics
1.3x6.9%US$369.0m
BBNX Beta Bionics
11.7x26.5%US$643.7m
BFLY Butterfly Network
8x18.8%US$617.0m
CBLL CeriBell
11.8x23.9%US$833.2m
VREX Varex Imaging
0.6x3.5%US$528.2m

Price-To-Sales vs Peers: VREX is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (8.2x).

Price to Sales Ratio vs Industry

How does VREX's PS Ratio compare vs other companies in the US Medical Equipment Industry?

52 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.2x7.7%
VREX Varex Imaging
 0.6x3.5%US$528.17m
ZYXI Zynex
0.6x8.9%US$223.39m
NVRO Nevro
0.5x3.9%US$218.94m
VREX 0.6xIndustry Avg. 3.2xNo. of Companies52PS02.85.68.411.214+
52 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.2x12.2%
VREX Varex Imaging
 0.6x147.5%US$528.17m
No more companies

Price-To-Sales vs Industry: VREX is good value based on its Price-To-Sales Ratio (0.6x) compared to the US Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is VREX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VREX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.6x
Fair PS Ratio0.7x

Price-To-Sales vs Fair Ratio: VREX is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VREX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$12.55
US$21.20
+68.9%
17.2%US$26.00US$15.00n/a5
Mar ’26US$12.86
US$21.20
+64.9%
17.2%US$26.00US$15.00n/a5
Feb ’26US$13.74
US$22.20
+61.6%
23.2%US$30.00US$16.00n/a5
Jan ’26US$14.59
US$22.20
+52.2%
23.2%US$30.00US$16.00n/a5
Dec ’25US$16.68
US$22.20
+33.1%
23.2%US$30.00US$16.00n/a5
Nov ’25US$13.20
US$22.20
+68.2%
23.2%US$30.00US$16.00n/a5
Oct ’25US$11.86
US$22.20
+87.2%
23.2%US$30.00US$16.00n/a5
Sep ’25US$12.48
US$22.20
+77.9%
23.2%US$30.00US$16.00n/a5
Aug ’25US$14.27
US$23.25
+62.9%
21.8%US$30.00US$17.00n/a4
Jul ’25US$14.29
US$23.25
+62.7%
21.8%US$30.00US$17.00n/a4
Jun ’25US$15.45
US$23.25
+50.5%
21.8%US$30.00US$17.00n/a4
May ’25US$16.58
US$27.88
+68.1%
21.5%US$36.00US$19.50n/a4
Apr ’25US$18.06
US$27.88
+54.3%
21.5%US$36.00US$19.50n/a4
Mar ’25US$17.29
US$27.88
+61.2%
21.5%US$36.00US$19.50US$12.864
Feb ’25US$19.56
US$28.25
+44.4%
19.4%US$36.00US$21.00US$13.744
Jan ’25US$20.50
US$28.25
+37.8%
19.4%US$36.00US$21.00US$14.594
Dec ’24US$18.80
US$29.50
+56.9%
13.9%US$36.00US$26.00US$16.684
Nov ’24US$18.10
US$36.25
+100.3%
23.6%US$47.00US$26.00US$13.204
Oct ’24US$18.79
US$36.25
+92.9%
23.6%US$47.00US$26.00US$11.864
Sep ’24US$19.94
US$36.25
+81.8%
23.6%US$47.00US$26.00US$12.484
Aug ’24US$23.01
US$35.75
+55.4%
25.7%US$47.00US$24.00US$14.274
Jul ’24US$23.57
US$35.75
+51.7%
25.7%US$47.00US$24.00US$14.294
Jun ’24US$22.08
US$35.75
+61.9%
25.7%US$47.00US$24.00US$15.454
May ’24US$17.54
US$35.25
+101.0%
27.9%US$47.00US$22.00US$16.584
Apr ’24US$18.19
US$35.25
+93.8%
27.9%US$47.00US$22.00US$18.064
Mar ’24US$17.68
US$35.25
+99.4%
27.9%US$47.00US$22.00US$17.294
Analyst Price Target
Consensus Narrative from 5 Analysts
US$21.20
Fair Value
40.8% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/12 06:14
End of Day Share Price 2025/03/12 00:00
Earnings2025/01/03
Annual Earnings2024/09/27

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Varex Imaging Corporation is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle BauserB. Riley Securities, Inc.
Lawrence SolowCJS Securities, Inc.
Rajbir DenhoyJefferies LLC